Skin Cancer: Merkel Cell Carcinoma

+ -Text Size

What`s New in Skin Cancer - Merkel Cell Research? TOPICS

What’s new in Merkel cell carcinoma research?

Research into the causes, prevention, and treatment of Merkel cell carcinoma (MCC) is under way in many medical centers throughout the world.

Causes of MCC

Scientists have made a great deal of progress in recent years in learning how ultraviolet (UV) light damages the DNA in skin cells, which might cause them to become cancer. Researchers are working to apply this information to help prevent and treat these and other skin cancers.

Researchers are also learning more about the Merkel cell polyomavirus (MCV), which has been found in most MCC tumors. It’s not yet clear exactly how damage from UV light, infection with MCV, and changes in the body’s immune system might interact to cause MCC, but this is an active area of research.

Prevention and early detection of MCC

Most skin cancers, including many MCCs, can be prevented. The best way to lower the number of skin cancers and the pain and loss of life from this disease is to educate the public, especially parents, about skin cancer risk factors and warning signs. It’s important for health care professionals and skin cancer survivors to remind others about the dangers of too much UV exposure (both from the sun and from man-made sources such as tanning beds) and about how easy it can be to protect your skin from UV rays.

MCC can often be found early, when it’s most likely to be cured. Monthly skin self-exams and awareness of the warning signs of MCCs and other skin cancers can be helpful in finding them when they are at an early, curable stage.

The American Academy of Dermatology (AAD) sponsors annual free skin cancer screenings throughout the country. Many local American Cancer Society offices work closely with AAD to provide volunteers for registration, coordination, and education efforts related to these free screenings. Look for information in your area about these screenings or call the American Academy of Dermatology for more information. Their phone number and website address are listed in Additional resources.


While early-stage MCCs often can be cured, more advanced MCCs can be much harder to treat. It’s been hard to study the best way to treat these cancers because they are not common. But in recent years, doctors have begun to look at newer types of treatment for this disease.


This type of treatment helps the body’s immune system attack cancer cells more effectively. Doctors are hopeful this approach might be useful against MCC, especially because this cancer appears to be linked to infection with a virus (MCV).

Immune checkpoint inhibitors: Immune system cells normally have substances that act as checkpoints to keep them from attacking other healthy cells. Cancer cells sometimes take advantage of these checkpoints to avoid being attacked by the immune system. Some newer drugs, such as pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) work by blocking these checkpoints, which boosts the immune response against cancer cells in the body. These drugs have already been shown to help people with advanced melanoma of the skin and some other cancers, and they are now being studied for use in MCC. Other new checkpoint inhibitors are being studied as well.

Autologous T cell therapy: In this approach, immune cells called T cells are removed from a person’s blood and exposed in the lab to parts of the Merkel cell polyomavirus (which is found in most MCC cells), along with chemicals to help activate the T cells. The cells are then infused back into the body. The hope is that these cells will now seek out and attack MCC cells. This approach is still in early phases of testing.

Hormone-like drugs

MCC is a type of neuroendocrine tumor, which means its cells share features with cells that normally make hormones in the body. Doctors are now testing whether drugs that affect hormone-making cells might be helpful against MCC. Examples include lanreotide (Somatuline Depot) and pasireotide (Signifor), which are in a group of drugs known as somatostatin analogs.

Some new drugs, such as 177Lu-DOTATATE, pair a somatostatin analog with a radioactive atom. These drugs should bind to the cancer cells, delivering the radiation to those cells and limiting the effects on normal cells. Research testing these types of drugs against MCC is still in very early phases.

Other new drugs

Newer drugs called targeted therapies may someday be shown to help treat MCC. Targeted therapies attack parts of cancer cells that make them different from normal cells. Each type of targeted therapy works differently, but they alter the way a cancer cell grows, divides, repairs itself, or interacts with other cells in some way. Targeted drugs are already used to treat many types of cancer, and some are now being studied for use against MCC.

Last Medical Review: 04/13/2015
Last Revised: 05/23/2016